Drug Trial Radar · NCT00863499
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
Last checked: Nov 19, 2026Latest source record: Jul 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,344
Planned (sponsor's estimate)
Start
Oct 2009
Primary completion
Dec 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- BRC Operations Pty. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Health services research
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of the iSPOT-A study is to: 1. identify brain, genetic and cognitive markers of Attention Deficit/Hyperactivity Disorder, and 2. identify brain, genetic and cognitive markers that predict treatment response to short-acting methylphenidate in children and adolescents diagnosed with Attention Deficit/Hyperactivity Disorder.
Conditions
- Attention Deficit/Hyperactivity Disorder
Interventions
Short Acting MethylphenidateDrug
Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.
Long Acting MethylphenidateDrug
Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine whether the genetic-brain-cognition function markers (or combination of markers) 'normalize' with acute drug treatment in ADHD.Time frame: 6 weeks
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Shanti Clinical Trials
Colton, California
Center for Healing the Human Spirit
Tarzana, California
Brain Resource Center
Englewood Cliffs, New Jersey
Brain Resource Center
New York, New York
Skyland Behavioral Health Associates , P.A.
Asheville, North Carolina
Brain Dynamics Centre
Westmead, New South Wales, Australia
Brainclinics Diagnostics B.V.
Nijmegen, Gelderland, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.